CD274 and non-small cell lung carcinoma: A phase 1/2 clinical trial (GALLANT-1; NCT05240131) is currently underway assessing the safety and efficacy of selvigaltin in combination with atezolizumab (anti-PD-L1 monoclonal antibody) versus placebo plus atezolizumab in patients with non-small cell lung cancer (NSCLC).